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Abstract 
Objective 
The stearoyl-CoA desaturase 1 (SCD1), also known as Δ9-desaturase, is a regulatory enzyme in 
the cellular lipid modification process that has been linked to pancreatic cancer and diabetes. The 
aim of the present study was to investigate the effect of peroxisome proliferative-activated 
receptor δ (PPARδ) agonist and ERK1/2- and EGF receptor (EGFR)-dependent pathways on the 
expression of SCD1 in human pancreatic carcinoma cell line PANC-1. 
Methods 
PANC-1 cells cultured in RPMI-1640 were exposed to the commonly used MEK inhibitor 
PD98059, EGFR-selective inhibitor AG1478, and PPARδ agonist GW0742. Changes in mRNA, 
protein expression and activity index of SCD1 were then determined using real-time reverse 
transcription polymerase chain reaction, Western blot and gas liquid chromatography, 
respectively. 
Results 
The activity index and expression of SCD1 (p<0.01) decreased following treatment with PPARδ 
agonist at both mRNA and protein levels, whereas significant increases were observed after 
treatment with MEK or EGFR inhibitor. It was also found that the activity index of SCD1 were 
lower (p<0.01) in the combined treatment compared to the incubation with either inhibitor alone. 
Conclusions 
PPARδ and MEK/ERK1/2- and EGFR-dependent pathways affect the expression and activity of 
SCD1 in pancreatic cancer cells. Furthermore, the aforementioned kinase signalling pathways 
were involved in an inhibitory effect on the expression and activity of SCD1 in these cells, 
possibly via PPARδ activation. 
 
